Reports Q4 revenue $281.9M, consensus $271.55M. “During fiscal 2023, our first full year as an independent company, we delivered better than expected performance during each quarter, including strong performance during our fiscal fourth quarter,” said Devdatt Kurdikar, CEO of embecta. “As we look ahead to fiscal 2024, we remain focused on advancing our strategic priorities and continuing to invest in the development of our type 2 closed loop insulin delivery system.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EMBC:
- Embecta Corp. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Provides Initial Fiscal 2024 Financial Guidance
- embecta Announces Quarterly Cash Dividend
- Embecta Corporation (EMBC) Q4 Earnings Cheat Sheet
- embecta to Recognize National Diabetes Awareness Month by Ringing Nasdaq Opening Bell
- embecta to Report Fiscal Fourth Quarter and Full Year 2023 Financial Results
